On May 6, 2024, Cellectis S.A., closed the transaction. As the result of the transaction, AstraZeneca PLC, now owns approximately 44% of the share capital and 30% of the voting rights of the company.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,596 GBX | +0.32% | +2.01% | +18.81% |
10:12am | JPMorgan cuts Aviva but lifts M&G | AN |
10:04am | Investors remain cautious as political instability takes over Europe |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
12,592 GBX | +0.29% | +2.01% | 248B | ||
2.315 EUR | -1.91% | -4.14% | 255M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.81% | 248B | |
+45.82% | 765B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
-1.15% | 219B | |
+11.17% | 216B | |
+5.90% | 164B | |
-0.73% | 162B | |
-0.52% | 123B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- Cellectis S.A. announced that it has received $140 million in funding from AstraZeneca PLC